There is a LOT to be excited about in this new study.
This statement at the end of it, is....maybe not one of them.... but they specifically limited access to these data in the IRB documentation, so even if you wonder what personal information could possibly be contained within a targeted antibody panel, it's against the rules to make this publicly available.
However - here we are with what might be the first win in ALS diagnostics with a proteomics technology in....ever....?
Surprisingly, it's actually a small cohort. It's less than 70 individuals? But with a pile of blood / plasma draws so it works out to ~550 samples. So....also evidence that O-Link Explore targeted panels can provide statistically valid data without an n>1000?
The end point isn't a new ALS diagnostic marker. It is, however, a panel of proteins that may allow earlier diagnosis. And maybe if it is caught earlier then there are ways to treat it and prolong lifespan and (as/more imporant) healthspan in this fucked up awful disease.
No comments:
Post a Comment